WO2009008632A3 - Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis - Google Patents
Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis Download PDFInfo
- Publication number
- WO2009008632A3 WO2009008632A3 PCT/KR2008/003950 KR2008003950W WO2009008632A3 WO 2009008632 A3 WO2009008632 A3 WO 2009008632A3 KR 2008003950 W KR2008003950 W KR 2008003950W WO 2009008632 A3 WO2009008632 A3 WO 2009008632A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastritis
- solubilized drug
- gastroretentive system
- therapeutic effect
- stomach
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is provided a gastroretentive system matrix formulation containing a compound represented by Formula 1 that has a therapeutic effect on gastritis and is solubilized in the stomach, and a method for preparing the gastroretentive system matrix formulation. The gastroretentive system matrix formulation according to the present invention may be useful to improve the solubility of a solubilized drug under an acidic condition in the stomach, and maximize an anti-inflammatory effect of the solubilized drug by increasing the retention time of the formulation in the stomach through the continuous release the solubilized drug into the stomach.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2007-0068368 | 2007-07-06 | ||
KR1020070068368A KR101381999B1 (en) | 2007-07-06 | 2007-07-06 | Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009008632A2 WO2009008632A2 (en) | 2009-01-15 |
WO2009008632A3 true WO2009008632A3 (en) | 2009-03-12 |
Family
ID=40229250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/003950 WO2009008632A2 (en) | 2007-07-06 | 2008-07-04 | Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101381999B1 (en) |
WO (1) | WO2009008632A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2463774T3 (en) * | 2007-11-12 | 2014-05-29 | Pharmaceutics International, Inc. | Trimolecular complexes and their use in drug delivery systems |
WO2011146611A1 (en) * | 2010-05-18 | 2011-11-24 | Abon Pharmaceuticals, Llc | Modified gastroretentive drug delivery system for amine drugs |
WO2017010487A1 (en) * | 2015-07-13 | 2017-01-19 | 協和発酵バイオ株式会社 | Tablets containing arginine at high concentration |
CN106905280B (en) * | 2017-02-24 | 2019-04-09 | 安徽医科大学 | Hesperetin analog derivative that a kind of amide groups replaces and preparation method thereof and as the application in the drug of anti-alzheimer's disease |
JP7458317B2 (en) * | 2017-10-31 | 2024-03-29 | サムヤン、ホールディングス、コーポレーション | Oral solid preparation composition with improved disintegration and method for producing the same |
US11511093B2 (en) | 2019-10-11 | 2022-11-29 | Wonkwang University Center for Industry Academy Cooperation | Gastroretentive drug delivery device having expandable structure and manufacturing method therefor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004541A1 (en) * | 1996-07-25 | 1998-02-05 | Dong A Pharmaceutical Co., Ltd. | Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease |
US6156343A (en) * | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
US6475521B1 (en) * | 1998-03-19 | 2002-11-05 | Bristol-Myers Squibb Co. | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
WO2005023244A1 (en) * | 2003-09-04 | 2005-03-17 | Dong-A Pharmaceutical Co., Ltd. | 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof |
KR20050098440A (en) * | 2004-04-07 | 2005-10-12 | 동아제약주식회사 | Rapid-acting oral formulation of artemisia extract using solid dispersion, processing method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100684099B1 (en) * | 2005-06-30 | 2007-02-16 | 주식회사 씨티씨바이오 | Composition containing clopidogrel free base |
-
2007
- 2007-07-06 KR KR1020070068368A patent/KR101381999B1/en active IP Right Grant
-
2008
- 2008-07-04 WO PCT/KR2008/003950 patent/WO2009008632A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156343A (en) * | 1994-12-27 | 2000-12-05 | Akzo Nobel N.V. | Controlled release preparation |
WO1998004541A1 (en) * | 1996-07-25 | 1998-02-05 | Dong A Pharmaceutical Co., Ltd. | Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease |
US6475521B1 (en) * | 1998-03-19 | 2002-11-05 | Bristol-Myers Squibb Co. | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
WO2005023244A1 (en) * | 2003-09-04 | 2005-03-17 | Dong-A Pharmaceutical Co., Ltd. | 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof |
KR20050098440A (en) * | 2004-04-07 | 2005-10-12 | 동아제약주식회사 | Rapid-acting oral formulation of artemisia extract using solid dispersion, processing method thereof |
Non-Patent Citations (1)
Title |
---|
BRIJESH S. DAVE ET AL.: "Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation.", AAPS PHARMSCITECH, vol. 5, no. 2, 8 April 2004 (2004-04-08), pages e34, XP055351630 * |
Also Published As
Publication number | Publication date |
---|---|
KR101381999B1 (en) | 2014-04-14 |
WO2009008632A2 (en) | 2009-01-15 |
KR20090004280A (en) | 2009-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA105229C2 (en) | Pharmaceutical formulation | |
WO2009008632A3 (en) | Gastroretentive system containing solubilized drug for maximizing its therapeutic effect for gastritis | |
EP2684573A3 (en) | Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis | |
GEP20135786B (en) | Pyrrole compounds | |
WO2009117150A3 (en) | Method of treating lupus with ceramide derivatives | |
MX2011012122A (en) | Thiophene derivatives. | |
NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
EP3492069A3 (en) | Pharmaceutical compositions | |
WO2007109057A3 (en) | Solid dosage form containing a taste masked active agent | |
MX2009004439A (en) | Ibuprofen composition. | |
MX2011013069A (en) | Solid compositions comprising 5-aminolevulinic acid. | |
MX2010003603A (en) | Method of treating polycystic kidney diseases with ceramide derivatives. | |
NZ592647A (en) | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester | |
WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | |
WO2010107807A3 (en) | Compounds for treating inflammation and pain | |
TN2010000135A1 (en) | Galenical formulations of organic compounds | |
UA96622C2 (en) | Solid dosage forms comprising aliskiren obtained by solvent-free granulation process | |
EP2361083A4 (en) | Composition for treatment of epithelial tissue | |
UA122762C2 (en) | ORAL COMPOSITION OF 9-[(2,2-DIMETHYLPROPYLAMINO)-METHYL]-MINOCYCLINE OR ITS SALTS, SOLID PRESSED DOSAGE FORM, COMPOSITION FOR INJECTIONS, APPLICATION AND METHOD OF PREPARATION OF THE PHARMACEUTICAL COMPOSITION | |
EP1935417A4 (en) | Composition for use in prevention of hypoglycemic condition | |
WO2009095624A3 (en) | Method for preparing dicaffeoylquinic acids and use thereof in combating aphids | |
EP2103610A4 (en) | The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use therrof | |
WO2011076209A3 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
GEP20125526B (en) | Drug active in neuropathic pain | |
WO2009011449A3 (en) | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08778613 Country of ref document: EP Kind code of ref document: A2 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08778613 Country of ref document: EP Kind code of ref document: A2 |